^
    Back
    Association details:
    Biomarker:TMB-H
    Cancer:Rectal Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Translational research of voltage-A1: Efficacy predictors of preoperative chemoradiotherapy and subsequent nivolumab monotherapy in patients with microsatellite-stable locally advanced rectal cancer.

    Published date:
    05/13/2020
    Excerpt:
    ...PD-L1-positive...and higher tumor mutation burden are good predictors of the efficacy of the sequential combination of CRT and nivolumab.
    DOI:
    10.1200/JCO.2020.38.15_suppl.4073